Market research

GLS Gelesis Holdings Inc

NYSE USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 12M
P/E ratio: Not available
Analyst target: 0.45
Dividend yield: 0.0%
Beta: 0.99

Loading price history…

Profile

Company facts

Exchange: NYSE
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US36850R2040
Market cap: 12M
P/E ratio: Not available
Analyst target: 0.45
Dividend yield: 0.0%
Beta: 0.99

About

About Gelesis Holdings Inc

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about GLS.

GLS Gelesis Holdings Inc

Price & volume

Company facts

About Gelesis Holdings Inc

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet